Raritan Pharmaceuticals, Inc. MARCS-CMS 516099 —
- Raritan Pharmaceuticals, Inc.
- Issuing Office:
Division of Pharmaceutical Quality Operations I
March 12, 2018
VIA UPS Next Day Air
Dr. Vin K. Nayak
Raritan Pharmaceuticals, Inc.
8 Joanna Ct.
East Brunswick, New Jersey 08816
Dear Dr. Nayak:
The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 17-NWJ-09, dated June 20, 2017. Based on our evaluation, it appears that you have addressed the violation(s) contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and it implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Liatte Krueger Closs